Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Genetic disorders stories

Oct 29, 2026

University of Eastern Finland identifies vitamin transporter protein for brain drug delivery

Researchers at the University of Eastern Finland have identified the SMVT transporter protein that can improve creatine delivery to the brain and potentially enable new therapies targeting the central nervous system. The discovery addresses one of medicine's greatest challenges: delivering drugs across the blood-brain barrier.

Oct 29, 2026·4 sources
00
Sep 25, 2026

FDA approves Mirum Pharmaceuticals' Atebrioz for fibrodysplasia ossificans progressiva

The FDA has approved Mirum Pharmaceuticals' Atebrioz (zilurgisertib), a once-daily pill for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder that causes soft tissue to turn to bone. This marks the third FDA-approved treatment for FOP, following recent approvals of Regeneron's Pasatru and Ipsen's Sohonos.

Sep 25, 2026·6 sources
00
Aug 28, 2026

Cytokinetics reports positive late-stage data for heart drug aficamten

Cytokinetics announced detailed late-stage trial results showing its drug aficamten significantly improved symptoms and exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy, a genetic heart condition with no approved treatments.

Aug 28, 2026·2 sources
00
Aug 18, 2026

Leo Pharma acquires worldwide rights to dersimelagon for up to $435M

Danish drugmaker Leo Pharma agreed to acquire worldwide rights to dersimelagon, a late-stage drug candidate for two rare genetic skin diseases, from Tanabe Pharma for up to $435 million in upfront and milestone payments.

Aug 18, 2026·2 sources
00
Aug 12, 2026

Prader-Willi syndrome experts raise safety concerns over Neurocrine's Vykat XR

Medical experts specializing in Prader-Willi syndrome flagged serious adverse events in patients taking Neurocrine Biosciences' drug Vykat XR, raising safety concerns about the treatment for the rare genetic disorder.

Aug 12, 2026·2 sources
00
Aug 11, 2026

Skylark Bio doses first patient in gene therapy trial for GJB2-related deafness

Skylark Bio has dosed the first patient in its SONIX Phase 1/2 trial of SKY-GJB2, a gene therapy targeting GJB2-related hearing loss, the most common genetic cause of pediatric deafness. The trial follows earlier breakthrough gene therapy treatments that restored hearing in children born deaf.

Aug 11, 2026·3 sources
00
Aug 7, 2026

Research explains immune system malfunction behind familial Mediterranean fever attacks

Scientists have identified why the body's inflammatory response misfires in familial Mediterranean fever, a hereditary autoinflammatory disease that causes the immune system to overreact to minimal stimuli, triggering recurrent fever attacks.

Aug 7, 2026·1 source
00
Aug 5, 2026

UK Approves First Trial of Moderna-Oxford mRNA Vaccine to Prevent Lynch Syndrome Cancers

UK regulators have authorized the INTERCEPT-Lynch Phase 1/2 trial of mRNA-4194, a preventive cancer vaccine developed by Moderna and the University of Oxford targeting people with Lynch syndrome, an inherited condition affecting 1 in 300 people with up to 80% lifetime cancer risk. The trial will begin dosing in summer 2026.

Aug 5, 2026·9 sources
00
May 5, 2026

Cytokinetics' Heart Disease Drug Myqorzo Meets Primary Endpoints in Phase 3 Trial for Genetic Heart Condition

Cytokinetics announced its heart disease drug Myqorzo, already approved in one indication, succeeded in meeting twin efficacy goals in a Phase 3 trial for genetic heart disease, potentially boosting future sales.

May 5, 2026·1 source
00
Apr 24, 2026

FDA Approves First Gene Therapy for Hereditary Hearing Loss

The FDA has greenlit a first-of-its-kind gene therapy to treat a rare form of hereditary hearing loss, marking a breakthrough that could pave the way for other hearing impairment treatments. Follow-up research confirms the therapy yields lasting hearing gains for patients with inherited deafness.

Apr 24, 2026·2 sources
00
Apr 22, 2026

Gene Therapy for Inherited Deafness Shows Lasting Hearing Restoration Years After Treatment

International clinical trial results show that gene therapy for a rare form of genetic deafness successfully restored hearing in 90% of participants, with improvements lasting years after treatment. The study was co-led by Mass General Brigham and China's Eye & ENT Hospital of Fudan University.

Apr 22, 2026·2 sources
00

Top claims

  • ▪Oral creatine supplementation fails to treat Creatine Transporter Deficiency Syndrome because ingested creatine cannot cross into the brain without a functional CRT1 transporter.
  • ▪Creatine Transporter Deficiency Syndrome (CTDS) is a rare X-linked neurological disorder affecting approximately 1 in 100,000 boys, caused by SLC6A8 gene mutations that impair the primary creatine importer CRT1.
  • ▪Researchers at the University of Eastern Finland identified that the sodium-dependent multivitamin transporter (SMVT) can transport creatine-derived prodrugs across the blood-brain barrier and into neurons.

Subtopics

Drug Approval and Clinical Trials6Drug Policy, Pricing & Approval5Clinical trials4Pharma4Gene therapy3Pharmaceutical Industry3Cardiovascular diseases2Clinical Trial Design & Evaluation2Drug development2FDA drug approval2Rare genetic diseases2Biomedical research1Biotechnology1Clinical evaluation1Clinical trial endpoints1Corporate strategy1Drug discovery1Drug safety1Inflammation1Media regulation1Medical research1Mergers & acquisitions (M&A)1MRNA vaccine technology1Neurological disorders1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories